Clinical Trial Update: An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the efficacy and safety of PROCRIT (epoetin alfa) in cancer patients receiving chemotherapy (weekly or every four weeks); the study has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Chemotherapy, Anemia | Phase 2 | Status: COMPLETED